Rheumatoid arthritis and osteoarthritis: disease pathogenesis
=============================================================

Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by the activation of synovial tissue lining the joint capsule, which results in the invasion of the cartilage and bone leading to the progressive joint dysfunction \[[@B1]\]. Severe morbidity and structural damage of joints caused by chronic inflammation often lead to major personal, family, and financial consequences, as well as increased mortality. Recent understanding of the RA pathogenesis has clarified the role of cytokines and other inflammatory mediators in this process and has provided a scientific rationale in the process of developing targeted therapies \[[@B2]\].

Osteoarthritis (OA) is a common disorder of synovial joints characterized pathologically by focal areas of damage to the articular cartilage, centered on load-bearing areas, which is associated with new bone formation at the joint margins (osteophytosis), changes in the subchondral bone, variable degrees of mild synovitis, and thickening of the joint capsule \[[@B3]\]. The severity of OA differs from patient to patient, but the very common clinical symptoms include pain, reduced range of motion, inflammation, and deformity \[[@B4]\]. This condition is strongly age related, being less common before the age of 40 but showing a marked increase in frequency with age \[[@B3]\]. Although OA is considered the disease of the destruction of articular cartilage, recent evidence suggests that it may also damage bone and synovium in the arthritic joints \[[@B3],[@B4]\]. Despite existing evidence of the crosstalk between tissues at the cellular and molecular levels, however, intertwined pathophysiological processes causing OA have reduced the focus in choosing from one of these three tissues - articular cartilage, bone, or synovium - to serve as the key therapeutic target \[[@B3]\].

Treatment of arthritis: approaches and options
==============================================

Conventional disease-modifying anti-rheumatic drugs such as methotrexate have long been the mainstay of RA treatment and are still advocated as a first-line option in newly diagnosed RA patients \[[@B5]\]. While a combination of good efficacy and acceptable toxicity, in conjunction with low cost and patient convenience, has made methotrexate an increasingly favored drug for RA, recent studies suggest that patients lose efficacy over time and only a minority of them achieve disease remission from its use \[[@B5]\]. TNFα inhibitors, as first-generation biologics, have radically changed the treatment of patients with refractory RA. Among patients with RA who are unresponsive to methotrexate, however, only two-thirds respond to TNFα inhibitors - which opened the option of combination therapy (combining disease-modifying anti-rheumatic drugs with biological therapy) \[[@B5],[@B6]\]. As a result, newer approaches have resulted in the development of next-generation biologics during the past few years, including abatacept, rituximab, and tocilizumab \[[@B2],[@B6]\].

Pharmacological management of OA includes analgesics and nonsteroidal anti-inflammatory drugs. Unfortunately, these medications can precipitate severe adverse reactions while providing only symptomatic relief from pain and no effect on the progress of OA in some patients \[[@B7]\]. In addition, increased rates of cardiovascular events associated with cyclooxygenase-2 (COX-2) inhibitors and some conventional nonsteroidal anti-inflammatory drugs have made the treatments inappropriate for long-term use by OA patients with high risk of heart disease or stroke \[[@B8]\]. More recent emerging data from clinical trials conducted over nine clinical centers in the United States underlined the clinical efficacy of a glucosamine and chondroitin sulfate combination on the progressive loss of cartilage, pain, and stiffness in patients with knee OA \[[@B7]\].

Plant-derived molecules for the treatment of arthritis
======================================================

The past decade or two have seen a dramatic increase and growing interest in the use of alternative treatments and herbal therapies by arthritis patients \[[@B9]-[@B11]\]. Trust-worthy documentation of traditional knowledge, together with extensive modern scientific/pharmacological experimentation, however, is necessary to validate or refute the purported medicinal value. In this regard, epigallocatechin-3-gallate (EGCG) has in the past decade been extensively evaluated by us and other researchers for its potential anti-rheumatic activity using *in vitro*experimentations and animal models of arthritis. The following section of the present review highlights some of these major findings and puts forward an argument for the future development of EGCG as a potential therapeutic entity for rheumatic diseases.

Epigallocatechin-3-gallate
==========================

Green tea (*Camellia sinensis*) is one of the most commonly consumed beverages in the world and is a rich source of polyphenols known as catechins (30 to 36% of dry weight) including EGCG, which constitutes up to 63% of total catechins \[[@B12]\]. EGCG has been shown to be 25 to 100 times more potent than vitamins C and E in terms of antioxidant activity \[[@B13]\]. A cup of green tea typically provides 60 to 125 mg catechins, including EGCG \[[@B14]\].

Efficacy of EGCG in arthritis
=============================

*In vitro*findings
------------------

### Cartilage/chondrocyte protection

Extensive studies in the past decade have verified the cartilage-preserving and chondroprotective action of EGCG. We pioneered research in this therapeutic area and studied the benefits of EGCG on progressive cartilage degradation, a hallmark of OA, using chondrocytes derived from OA cartilage. Pro-inflammatory cytokines such as IL-1β, TNFα, and IL-6 have been shown to modulate extracellular matrix turnover, to accelerate the degradation of cartilage, and to induce apoptosis in chondrocytes \[[@B3],[@B4]\].

Besides promoting imbalance between excessive cartilage destruction and cartilage repair processes, IL-1β has been a potent inducer of reactive oxygen species, including nitric oxide and inflammatory mediators such as prostaglandin E~2~, via enhanced expression of the enzymes inducible nitric oxide synthase and COX-2, respectively \[[@B15],[@B16]\]. Preincubation of human chondrocytes derived from OA cartilage at different micromolar concentrations of EGCG showed a marked inhibition in the IL-1β-induced inducible nitric oxide synthase and COX-2 expression and activity, which further resulted in the reduced nitric oxide and prostaglandin E~2~synthesis \[[@B15],[@B16]\]. Defining the molecular mechanism of EGCG\'s efficacy in regulating inducible nitric oxide synthase expression, the results showed that EGCG inhibits IL-1β- induced phosphorylation and proteasomal degradation of IκBα to suppress NF-κB nuclear translocation \[[@B16]\].

In a follow-up study to determine the effect of EGCG on other signaling pathways triggered by IL-1β, Singh and colleagues showed that EGCG selectively inhibited the p46 isoform of c-Jun-N-terminal kinase induced by IL-1β \[[@B17]\]. This resulted in the reduced accumulation of phosphorylated c-Jun and activation protein-1 DNA binding activity, and of activation protein-1-mediated inflammatory responses in OA chondrocytes.

Under normal circumstances, chondrocytes in the cartilage make extracellular matrix components such as aggrecan and type II collagen as required in response to mechanical pressure \[[@B3]\]. Under abnormal or diseased conditions, however, chondrocyte metabolism is altered under the influence of the increased influx of pro inflammatory cytokines that activate matrix-degrading enzymes termed matrix metalloproteinases (MMPs) and of reactive mediators that promote cartilage degradation \[[@B18]\]. MMPs are a large group of enzymes that play a crucial role in tissue remodeling as well as in the destruction of cartilage in arthritic joints due to their ability to degrade a wide variety of extracellular matrix components \[[@B19],[@B20]\]. Interestingly, the collagenases among the MMP family are of particular importance in joint disorders due to their ability to efficiently cleave type II collagen \[[@B19],[@B20]\].

In another study, we evaluated the potential of EGCG to protect human cartilage explants from IL-1β-induced release of cartilage matrix proteoglycans and the induction and expression of MMP-1 and MMP-13 in human chondrocytes \[[@B21]\]. Our results showed that EGCG pretreatment of cultured human OA chondrocytes significantly inhibited the expression and activities of MMP-1 and MMP-13 in a dose-dependent manner \[[@B21]\]. In a parallel observation, another study found that catechins from green tea inhibited the degradation of human cartilage proteoglycan and type II collagen, and selectively inhibited ADAMTS-1, ADAMTS-4, and ADAMTS-5 \[[@B22],[@B23]\]. Further evaluation of the effect of EGCG on the anabolic pathways in chondrocytes showed that EGCG ameliorates IL-1β-mediated suppression of transforming growth factor β synthesis, and enhances type II collagen and aggrecan core protein synthesis in human articular chondrocytes \[[@B24]\]. These results were further supported by a recent study showing the protective effect of EGCG on advanced glycation end product-induced MMP-13 production in human OA chondrocytes *in vitro*\[[@B25]\].

To further support the chondroprotective effects of EGCG in arthritis, a recent study conducted by the biomaterial testing group on collagen showed that collagen preincubated with EGCG demonstrated a remarkable resistance against degradation by bacterial collagenase and MMP-1 \[[@B26]\]. A circular dichroism spectral analysis of the triple-helical structure of EGCG-treated collagen and untreated collagen showed a higher free-radical scavenging activity in EGCG-treated collagen \[[@B26]\]. Recent studies evaluating the cartilage-preserving property of EGCG showed that articular cartilages, preserved in a storage solution containing EGCG for up to 4 weeks, showed a higher degree of chondrocyte viability and proteoglycan (GAG) content of the extracellular matrix, at least in part, by reversibly regulating the cell cycle at the G0/G1 phase and NF-κB expression \[[@B27],[@B28]\]. These findings provide a scientific rationale for the efficacy of EGCG in protecting cartilage breakdown during the progress of joint disorders and could be utilized in other chronic ailments where integrity of the collagen is compromised in tissue destruction or remodeling.

### Bone-preserving activity

In rheumatic diseases, loss of the intricate balance between bone formation and bone resorption activity leads to skeletal abnormalities that affect the quality of life \[[@B29]\]. In particular, three TNF family molecules - the receptor activator of NF-κB, its ligand RANKL, and the decoy receptor of RANKL, osteoprotegerin - have established their pivotal role as central regulators of osteoclast development and osteoclast function \[[@B29]\]. In 2006 Hafeez and colleagues showed that green tea polyphenols triggered caspase-3-dependent apoptosis in these cells by regulating the constitutively active NF-κBp65 to induce DNA fragmentation and apoptosis in osteocarcoma SaOS-2 cells \[[@B30]\]. Another recent study using human osteoblastic cells evaluated the effect of EGCG on oncostatin M-induced monocyte chemotactic protein-1 (MCP-1)/CCL2 synthesis \[[@B31]\]. The experimental findings of the study suggested that EGCG inhibits oncostatin M-induced MCP-1/CCL2 synthesis in human osteoblastic and MG-63 cells by reducing c-Fos synthesis \[[@B31]\].

IL-6 - produced by both stromal cells and osteoblasts in response to several stimuli such as lipopolysaccharides IL-1β, and TNFα- stimulates bone resorption and osteoclast formation \[[@B32],[@B33]\]. The efficacy of EGCG was evaluated against basic fibroblast growth factor-2-induced IL-6 synthesis in osteoblast-like MC3T3-E1 cells \[[@B34]\]. EGCG inhibited basic fibroblast growth factor-2-induced IL-6 synthesis dose dependently and, in part, via suppression of ERK1/2 and p38 mitogen-activated protein kinase pathways in osteoblast cells \[[@B34]\]. Further extending these findings, a recent study by Kamon and colleagues showed that EGCG reduced osteoclast formation in these cells by inhibiting osteoblast differentiation without affecting their viability and proliferation \[[@B35]\]. Another recent study addressing the precise molecular mechanism through which EGCG inhibits osteoblast differentiation showed that EGCG produced an anti-osteoclastogenic effect by inhibiting RANKL-induced activation of c-Jun-N-terminal kinase and NF-κB pathways, thereby suppressing the gene expression of c-Fos and NFATc1 in osteoclast precursors \[[@B36]\].

### Regulation of synovial fibroblast activity

Under normal physiological conditions, synovial fibroblasts form a thin lining of synovial tissue surrounded by the fibrous capsule of the joint. The lining of synovial fibroblasts secretes synovial fluid, which has both lubricating and immunomodulatory properties, and which promotes normal joint function. In diseased conditions such as RA, synovial fibroblasts in the RA synovium become hyperproliferative and secrete factors that promote inflammation, neovascularization, and cartilage degradation.

In response to cytokines produced by macrophages such as TNFα and IL-1β, RA synovial fibroblasts secrete matrix-degrading enzymes such as MMPs, ADAMTS, and cathepsins. MMPs released from RA synovial fibroblasts can modulate activity of cytokines and chemokines, release proapoptotic ligands from cell surfaces, and promote fibroblast invasion of the cartilage. RA synovial fibroblasts also attract leukocytes by expressing chemokines in response to cytokines via distinct signaling pathway, which provides an opportunity to target them for different therapeutic approaches.

We and other workers have extensively evaluated the efficacy of EGCG using the synovial fibroblasts isolated from human joints to provide the exact mechanism through which EGCG inhibits or suppresses arthritis. Our study showed that EGCG pretreatment significantly inhibited both the constitutive and IL-1β-induced chemokine MCP-1/CCL2 production, regulated upon activation, normal T-cell expressed and secreted (RANTES/CCL5) production, growth-regulated oncogene (Gro-α/CXCL1) production, and epithelial neutrophil-activating peptide 78 (ENA-78/CXCL5) production, and MMP-2 activation by RA synovial fibroblasts \[[@B37]\]. This was achieved by EGCG via selective inhibition of the IL-1β-induced protein kinase Cδ and NF-κB pathways. One step further, we found that EGCG significantly inhibited MMP-2 activity induced by RANTES/CCL5, Gro-α/CXCL1, and ENA-78/CXCL5, suggesting a novel mechanism of MMP-2 regulation by EGCG in RA synovial fibroblasts \[[@B37]\]. In our follow-up study, we observed a similar inhibitory effect of EGCG-containing green tea extract (GTE) on chemokine synthesis in RA synovial fibroblasts \[[@B38]\]. GTE preincubation surprisingly induced the basal and IL-1β-induced chemokine receptor expression in these cells, however, which was also mimicked by the protein kinase Cδ inhibitor, Rottlerin \[[@B38]\]. Further studies are underway to clarify the significance of these findings in relation to GTE\'s anti-arthritic property.

It has also been shown that EGCG was effective in inhibiting IL-1β-induced MMP-1, MMP-3, and MMP-13 in human tendon fibroblasts \[[@B39]\]. Synovial fibroblast IL-6 production has been shown to inhibit bone formation and to concomitantly stimulate bone resorption and pannus formation \[[@B40]\]. In this regard, we showed in our recent study that EGCG pretreatment inhibits IL-1β-induced IL-6 and vascular endothelial growth factor synthesis in RA synovial fibroblasts \[[@B41]\]. In a recent study, Yun and colleagues showed that EGCG treatment resulted in dose-dependent inhibition of TNFα-induced production of MMP-1 and MMP-3 at the protein and mRNA levels in RA synovial fibroblast by inhibiting activation protein-1 DNA binding activity \[[@B42]\].

In RA, the purposeful induction of apoptosis in activated synovial fibroblasts has emerged as a therapeutic strategy for halting deleterious tissue growth \[[@B1]\]. The constitutive activation of survival protein Akt and NF-κB in RA synovial fibroblasts makes these cells resistant to both TNFα-mediated and Fas-mediated apoptosis \[[@B43],[@B44]\]. In recent years, studies have linked the overexpression of the anti-apoptotic myeloid cell leukemia-1 (Mcl-1) protein as a major cause of RA synovial fibroblast resistance to apoptosis \[[@B1],[@B45]\]. Our recent study to evaluate the efficacy of EGCG in downregulating Mcl-1 expression showed that, in RA synovial fibroblasts, EGCG inhibits constitutive and TNFα-induced Mcl-1 protein expression \[[@B46]\]. Importantly, EGCG specifically abrogated Mcl-1 expression in RA synovial fibroblasts and affected Mcl-1 expression to a lesser extent in OA synovial fibroblasts, normal synovial fibroblasts, and endothelial cells. In this study, caspase-3 activation by EGCG also suppressed RA synovial fibroblast growth, and this effect was mimicked by Akt and NF-κB inhibitors. Interestingly, Mcl-1 degradation by EGCG sensitized RA synovial fibroblasts to TNFα-induced cleavage of poly ADP-ribose polymerase protein and apoptosis. Our finding suggests that EGCG may selectively induce apoptosis and further sensitize RA synovial fibroblasts to TNFα-induced apoptosis to regulate their invasive growth in RA.

Animal studies
--------------

### Collagen-induced arthritis

The potential disease-modifying effect of EGCG on arthritis was first discovered in a study in which the consumption of EGCG-containing GTE in drinking water ameliorated collagen-induced arthritis (CIA) in mice \[[@B47]\]. The reduced CIA incidence and severity was reflected in a marked inhibition of the inflammatory mediators COX-2, IFNγ, and TNFα in arthritic joints of green tea-fed mice. Additionally, total immunoglobulins (IgG) and type II collagen-specific IgG levels were found to be lower in serum and arthritic joints of green tea-fed mice \[[@B47]\].

Interestingly, some recent pharmacological studies using EGCG or green tea to suppress arthritis have focused equally on bone resorption observed in RA \[[@B31],[@B48]-[@B51]\]. A recent study by Morinobu and colleagues showed that EGCG treatment reduced bone resorption as determined by tartrate-resistant acid phosphatase-positive multinucleated cells, bone resorption activity, and osteoblast-specific gene expression of the transcription factor NF-ATc1, but not of NF-κB, c-Fos, and c-Jun \[[@B49]\]. The *in vivo*effect of osteoclast differentiation in CIA mice was not clear, however, as intraperitoneal administration of EGCG (20 mg/kg) inhibited inflammation in experimental arthritis \[[@B49]\]. Using *in vivo*testing conducted in mouse CIA model, another study showed that EGCG (20 mg/kg, intraperitoneally daily) ameliorated arthritis and macrophage infiltration, and caused a reduction in the amount of MCP-1/CCL2-synthesizing osteoblasts \[[@B31]\].

### Adjuvant-induced arthritis

Recent advances in understanding the pathogenic effects of IL-6 provide evidence of its central role in promoting acute inflammation \[[@B32],[@B33]\]. Further studies related to the mechanisms through which EGCG inhibits inflammation and tissue destruction in RA were studied by us and others. Our novel findings showed that EGCG selectively inhibits IL-6 synthesis in rat adjuvant-induced arthritis, thus providing a missing link to the reduction in inflammation observed in earlier studies \[[@B41]\]. Administration of EGCG (100 mg/kg, intraperitoneally daily) during the onset of arthritis in rats resulted in a specific inhibition of IL-6 levels in the serum and joints of EGCG-treated animals. Our study also showed that EGCG enhances the synthesis of soluble gp130 protein, an endogenous inhibitor of IL-6 signaling and trans-signaling \[[@B41]\]. The inhibition of arthritis in EGCG-treated rats correlated to the reduction in MMP-2 activity in the joints compared with the activity level in arthritic rats \[[@B41]\].

A recent study testing a possible immunomodulatory activity of GTE in arthritis showed that GTE administration in drinking water ameliorated rat adjuvant-induced arthritis via the inhibition of serum IL-17 levels, with a concomitant upregulation of serum IL-10 levels \[[@B52]\]. In our recent study, a daily per oral administration of GTE (200 mg/kg) modestly ameliorated rat adjuvant-induced arthritis, which was accompanied by a decrease in MCP-1/CCL2 and GROα/CXCL1 levels and enhanced CCR-1, CCR-2, CCR-5, and CXCR1 receptor expression in the joints of GTE-administered rats \[[@B38]\]. This suggests that chemokine receptor overexpression with reduced chemokine production by GTE may be one potential mechanism to limit the overall inflammation and joint destruction in RA. Further studies may be designed to improve the clinical outcome in animal models of RA through modification of the dose and frequency of GTE administration, which may provide a better outcome and benefits of GTE in RA.

Clinical studies
----------------

The efficacy of EGCG or GTE in human RA or OA using the phase-controlled trials is yet to be tested. Several phase I and phase II cancer chemoprevention trials, however, have been performed using EGCG or GTE. A study by Elmets and colleagues showed that EGCG provided photoprotection to the skin from ultraviolet radiation on topical application in healthy human volunteers \[[@B53]\]. In another study, patients suffering from chronic lymphocytic leukemia showed an improvement in their clinical, laboratory, and radiographic outcomes and objective responses \[[@B54]\] after oral ingestion of EGCG. The results of a recent open-label, phase II clinical trial using EGCG in prostate cancer patients showed a significant decrease in the serum levels of prostate-specific antigen, hepatocyte growth factor, and vascular endothelial growth factor after 6 weeks of treatment \[[@B55]\]. A phase I trial on EGCG, with a 400 to 2,000 mg dose taken by mouth twice a day for month, was well tolerated by chronic lymphocytic leukemia patients, the majority of whom showed a decline in lymphocyte count and lymphadenopathy \[[@B56]\]. This has encouraged the investigators of the study to initiate a phase II trial to evaluate EGCG efficacy using a 2,000 mg dose twice daily \[[@B56]\].

The efficacy of EGCG in human metabolic disorders has been a topic of clinical interest. A randomized, controlled clinical trial using EGCG on insulin resistance and associated metabolic risk factors in obese men showed that 400 mg EGCG treatment twice daily for 8 weeks showed no effect on insulin sensitivity or secretion and glucose tolerance, but caused a moderate reduction in blood pressure and a positive effect on mood \[[@B57]\]. In another study by Maki and colleagues, the consumption of 625 mg EGCG-containing catechins daily for 12 weeks caused a greater loss of body weight and a decrease in the fasting serum triglyceride levels in the catechin-administered group \[[@B58]\]. In a double-blind, placebo-controlled trial, intake of GTE (containing 302 mg EGCG) for 12 weeks showed a significant reduction in the levels of low-density lipoprotein and triglyceride, and markedly increased the high-density lipoproteins and adiponectin levels \[[@B59]\].

EGCG: bioavailability and possible drug interactions
====================================================

Pharmacokinetics of EGCG
------------------------

The pharmacokinetics and bioavailability of EGCG in rodents and humans is well studied. An acute and short-term toxicity study on EGCG preparations showed that the dietary consumption of EGCG by rats for 13 weeks was nontoxic at doses up to 500 mg/kg/day \[[@B60]\]. A study by Chen and colleagues showed that administration of pure EGCG or EGCG in the form of decaffeinated GTE to rats via intravenous or intragastric administration showed differences in the pharmacokinetic patterns, favoring the intravenous route when given as an extract \[[@B61]\]. Studies also revealed that EGCG possesses a longer half-life and a smaller clearance rate, suggesting a slower rate of elimination of EGCG as compared with epigallocatechin and epicatechin \[[@B61]\]. A study by Kim and colleagues, in which subjects consumed GTE at 0.6% in drinking water over 28 days, showed that EGCG is more available in free form as compared with other catechins \[[@B62]\]. These studies also showed that the highest concentration of EGCG was found in the large intestine, suggesting a higher absorption rate but less clearance - as demonstrated by the lower levels of EGCG detected in plasma and distributed in the kidney, liver, lungs, and prostate of rats \[[@B61],[@B62]\]. In contrast to the results with rats, however, the level of EGCG in mice was much higher than that of epigallocatechin and epicatechin, suggesting a high bioavailability of EGCG in mice \[[@B62]\]. In addition, it was reported that the intraperitoneal administration of green tea containing EGCG showed much higher tissue and plasma concentration of EGCG than that obtained intragastrically \[[@B62]\]. Although other chemical processes such as peracetylation and glucuronidation have been shown to enhance the bioavailability of EGCG, not much is known about the distribution and its bioactivity in diseased conditions.

In humans, EGCG has been extensively studied for its acute and long-term toxicity studies \[[@B63]-[@B66]\]. A standardized capsule of polyphenon E containing 400 mg, 800 mg, or 1,200 mg EGCG was used to study the pharmacokinetics of EGCG in humans \[[@B63],[@B64]\]. The pharmacokinetic analysis from the study showed that the average plasma area under the curve, the maximum concentration, and the half-life increased with an increase in the dosages given in the capsules of 400 mg, 800 mg, and 1,200 mg EGCG \[[@B64]\]. This study also showed that administration of EGCG capsules to human subjects under fasting conditions significantly enhanced the pharmacokinetic profile and bioavailability of EGCG, possibly due to reduced conversion by glucuronidation process \[[@B64]\]. A 4-week clinical study carried out to determine the safety and pharmacokinetics of EGCG at doses of 400 and 800 mg/day in healthy participants showed no significant adverse effects, and investigators observed a significant (\>60%) increase in EGCG bioavailability by the 800 mg/day dose, when compared with the 400 mg/day dose, in these participants \[[@B63]\]. There are, however, limited numbers of studies suggesting that the EGCG plasma concentration may reach up to \~1 μM when consumed by drinking green tea \[[@B67],[@B68]\]. Further studies are required to optimize the circulating and synovial concentrations of EGCG to avail benefits similar to those observed *in vitro*and in preclinical studies.

Drug interaction
----------------

There have been limited data available to validate or reject the potential benefit of EGCG in RA patients. Studies conducted recently, however, evaluate the efficacy of EGCG in combination with conventional medicine, which could be extrapolated for possible interaction with anti-rheumatic drugs. The initial observation came from the anti-cancer studies using EGCG, wherein the administration of EGCG was shown to enhance the apoptosis-inducing property of COX-2 inhibitors on the growth of human prostate cancer cells *in vitro*and *in vivo*\[[@B69]\]. In another related study, EGCG sensitized human prostate carcinoma LNCaP cells to TNF-related apoptosis-inducing ligand-induced apoptosis and synergistic inhibition of the biomarkers of angiogenesis and metastasis \[[@B70]\]. Similar outcomes on the sensitization of RA synovial fibroblasts for TNF-related apoptosis-inducing ligand-induced apoptosis were observed with trichostatin A, suggesting a common mechanism of regulating invasive growth of synovial tissue in RA \[[@B71]\].

Another unique mechanism through which EGCG leaves a positive impact as a potential therapeutic option comes from its property of inducing pretranscriptional modification, termed alternative splicing. In addition to our study, where EGCG enhanced the synthesis of soluble gp130 at least in part by this mechanism, recent reports suggest that EGCG modulates alternative splicing to correct mutated proteins to normal forms, as observed for survival motor neuron-1 protein in neurodegenerative disorder, or to produce spliced variants of Mcl-1 and Bcl-X proteins in combination with ibuprofen that may inhibit the functionality of these anti-apoptotic proteins in prostate cancer cells \[[@B41],[@B72],[@B73]\]. More recently, conflicting results have emerged from the studies related to the effect of EGCG on clinical efficacy of the chemotherapeutic agent Bortezomib as a proteasome inhibitor in cancer-related studies \[[@B74],[@B75]\]. More elaborative and rigorous studies are awaited, however, to verify the possible interaction of EGCG with current treatment modalities for rheumatic diseases - in particular, biological therapies and methotrexate treatment.

Development of synthetic analogs of EGCG: future implications
-------------------------------------------------------------

The growing interest of pharmacologists in studying EGCG was never hidden from medicinal chemists, which led to the development of synthetic analogs of EGCG \[[@B76]\]. Zaveri and colleagues reported the synthesis of a trimethoxybenzoyl ester (D-ring) analog of EGCG, which was found to be equally as potent as natural EGCG for its efficacy as an anti-carcinogenic agent \[[@B77]\]. In addition, there have been some recent efforts to enhance its bioavailability by delivering EGCG using lipid nanocapsules and liposome encapsulation, suggesting the possibility of this molecule being developed further by medicinal chemists \[[@B78]\]. In this direction, there has been a successful *in vitro*and *in vivo*testing of delivering EGCG in polylactic acid-polyethylene glycol nanoparticles to inhibit angiogenesis and induce apoptosis \[[@B79]\]. Similarly, the results from a recent study suggest that nanolipidic EGCG particles significantly improved the neuronal α-secretase enhancing ability and possessed the oral bioavailability more than twofold over free EGCG for the treatment of Alzheimer\'s disease \[[@B80]\].

Conclusions and future implications
===================================

The present review summarizes the translational research for the validation of the purported benefits of EGCG in preclinical and clinical settings. An extensive evaluation of the potential risks or benefits of using EGCG alone or together with anti-rheumatic drugs may open a new area of research wherein EGCG or its synthetic analogs could be developed to enhance its clinical appeal. Extensive research on the benefits of EGCG in other chronic ailments such as carcinogenesis and cardiovascular diseases using clinical trials has shown promise \[[@B81],[@B82]\]. With the availability of the safety profile and pharmacokinetics of EGCG in phase I trials in humans, the window of opportunity is even wider to test EGCG for its potential therapeutic efficacy as an anti-rheumatic entity in human RA or OA. In conclusion, for the scientists and clinicians in the research area of drug discovery, EGCG represents a much safer molecule worth testing in humans, as the positive outcomes of such studies may have potential for its rapid clinical development and application.
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